Market Overview

Simoa Technology Unlocks Insights from Previously Obscure Biomarker

Share:

Neurofilament light chain (NfL) proves to be a transformative
biomarker for understanding wide range of neurological conditions and
advancing clinical trials

Quanterix
Corporation
(NASDAQ:QTRX), a company digitizing biomarker analysis
to advance the science of precision health, today announced its
ultra-sensitive Simoa technology is making it possible for researchers
to uncover significant novel applications for the brain biomarker
neurofilament light chain (NfL) to advance the early detection,
treatment and prevention of neurological diseases, including multiple
sclerosis (MS); Parkinson disease; Alzheimer disease; brain cancer; and
traumatic brain injuries (TBIs).

"NfL is rapidly emerging as a critical biomarker providing novel
insights into an incredibly wide range of applications, and its
potential to impact healthcare is staggering," said Kevin Hrusovsky,
CEO, President and Chairman of Quanterix and Founder of Powering
Precision Health. "Using Simoa, researchers are now, for the first time,
able to measure NfL in blood, vastly expanding the number and breadth of
studies possible and providing insights into disease progression,
patient response and drug performance, and accelerating drug development
that was never possible before."

Research
powered by Simoa continues to prove NfL as a critical biomarker for the
transformation of precision health. Specific applications include, but
are not limited to:

  • NfL as a biomarker for the diagnosis of minor head injuries (Journal
    of Neurosurgery
    )
  • NfL as a dynamic biomarker of brain atrophy in Huntington disease (Neurology)
  • NfL as a promising noninvasive biomarker for Alzheimer disease (JAMA
    Neurology
    )
  • NfL as a sensitive and clinically meaningful blood biomarker to
    monitor MS and effective therapies for the disease (Annals
    of Neurology
    )
  • NfL as a biomarker to distinguish between Parkinson disease and
    atypical parkinsonian disorders (APD) with unprecedented accuracy (Neurology)
  • NfL as a reliable biomarker for the diagnosis of concussions,
    specifically in contact sports (Journal
    of Neurotrauma
    )
  • NfL as a biomarker of brain cancer (brain metastases and glioma
    activity) presented at ASCO

"NfL is quickly emerging as one of the most relevant biomarkers in
neurology," said Dr. Henrik Zetterberg, Department of Psychiatry and
Neurochemistry at the University of Gothenburg, Sweden. "For years its
power as a blood test eluded the scientific community, as we lacked the
sensitivity necessary to truly see its impact. Today, however, we're
able to detect and quantify the biomarker, and are learning about new
potentially groundbreaking applications nearly every day."

Blood measurements of NfL have recently become a hot topic for the
monitoring and development of MS drugs, as further outlined in two
recently published papers in the journal Brain. The
first paper
presents data that confirms serum NfL levels are higher
in patients with MS as compared to healthy controls, and that higher NfL
levels were an independent predictor of worsening disability the
following year. Further, the higher the serum NfL levels, the more
pronounced future brain and spinal cord volume loss on MRIs were.

Simoa has also demonstrated the potential of NfL as a viable biomarker
for improving the drug development process and for advancing clinical
trials that are testing treatments to cure MS and other diseases.
Currently, clinical trials rely heavily on MRIs as a clinical endpoint
measurement of drug efficacy. Unfortunately, MRIs are not very sensitive
or accurate. The
second article
lays out the widely used clinical criteria for a new
biomarker to be considered a surrogate endpoint, which would enable
pharmaceutical researchers to monitor changes to the disease shortly
after administering a drug to more quickly see its impact.

"When we look at MS for example, there are approximately 2.5 million
patients living with the disease. These patients average about 1.5 scans
per person, per year. These scans, however, measure brain atrophy, which
is a very late stage measurement of the disease, usually not seen until
after the disease has ravaged the body and when it's much less
treatable," continued Hrusovsky. "Biomarkers like NfL can change the
practice of medicine, enabling us to catch diseases earlier, identify
impactful treatment methods faster, and check to ensure a drug is having
the desired impact."

To learn more about Quanterix' NfL assay, click
here
.

About Quanterix
Quanterix is a company that's digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company's digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease through ultrasensitive detection of biomarkers and to accelerate
drug development and approval. Quanterix' technology is designed to
enable much earlier disease detection, better prognoses and enhanced
treatment methods to improve the quality of life and longevity of the
population for generations to come. The technology is currently being
used for research applications in several therapeutic areas, including
oncology, neurology, cardiology, immunology and infectious disease. The
company was established in 2007 and is located in Lexington,
Massachusetts. For additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "may," "will," "expect,"
"plan," "anticipate," "estimate," "intend" and similar expressions (as
well as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix'
expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties.
Factors that may cause Quanterix' actual results to differ from those
expressed or implied in the forward-looking statements in this press
release are discussed in Quanterix' filings with the U.S. Securities and
Exchange Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Quanterix assumes no obligation to
update any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes available.

View Comments and Join the Discussion!